Carlos Iniesta

Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual, and other men who have sex with men in Spain

Background Lenacapavir (LEN), a twice-yearly subcutaneous capsid inhibitor, has demonstrated superior efficacy over daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as HIV pre-exposure prophylaxis (PrEP) in clinical trials. No European cost-effectiveness analyses...